Introduction On October 2nd 2020, the FDA approved Opdivo (Nivolumab) in combination with Yervoy (Ipilimumab) for the first-line treatment of patients with Malignant Pleural Mesothelioma that cannot be removed by…
Background DNA damage is the fundamental cause of cancer – leading to mutations in key genes that allow cancer cells to divide uncontrollably. But it can also be a key…
Background 3-year follow-up results from the randomized phase II study assessing the efficacy and safety of Debio 1143 in combination with chemo-radiation therapy vs. chemo-radiation therapy alone. The treatment was…
Background Breast cancer affects one in eight women. Around 80% are categorized as estrogen receptor-positive, or ER-positive. This means the cancer cells have receptors - molecules that can receive signals…
Background - Endometrial cancer and this trial Uterine-serous-carcinoma, USC, is an aggressive variant of endometrial cancer. This phase II trial evaluated Carboplatin+Taxol versus Herceptin +Carboplatin+Taxol in patients with advanced or…
Berzosertib - Trial Rational Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA repair, “ATR kinase”. Blocking this…
Background Enhertu is a conjugate of an antibody which is anti-HER2 and chemo drug. Enhertu may have efficacy in patients with HER2-positive advanced gastric cancer. In a phase II trial,…
Background Pyrotinib is an innovative cancer drug targeting EGFR, HER2, and HER4 which are components expressed on cell surface. Pyrotinib plus Xeloda has shown meaningful benefits and acceptable side effects…
Colon cancer treated with Enhertu Enhertu is an antibody-drug conjugate composed of a chemotherapy bound to an anti-HER2 antibody. Recently, in December 2019, Enhertu received accelerated approval by the FDA…
About the two study drugs in Triple Negative Breast Cancer Both study drugs are FDA approved. Halaven is approved for advanced breast cancer and Keytruda for different cancer indications. As…